Developing a biosimilar of Amgen's Enbrel treatment for inflammatory diseases.
Industry: Health Care
First Day Return: -6.6%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 09/25/2014 |
Offer Price | $13.50 |
Price Range $12.00 - $15.00 | |
Offer Shares (mm) | 6.3 |
Deal Size ($mm) | $85 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 11/06/2014 |
Offer Price | IPO Intelligence Only |
Price Range | IPO Intelligence Only |
Offer Shares (mm) | IPO Intelligence Only |
Deal Size ($mm) | $85 |
Lock-Up Date | IPO Intelligence Only |
Street Research | IPO Intelligence Only |
Underwriters |
---|
IPO Intelligence Only |
Company Data | |
---|---|
Headquarters | Redwood City, CA, United States |
Founded | 2010 |
Employees at IPO | 46 |
Website www.coherus.com |